Evidence map›Paper›PMID 37642893›Full record

ArticleNeurochemical research2024

Necrostatin-1s Suppresses RIPK1-driven Necroptosis and Inflammation in Periventricular Leukomalacia Neonatal Mice.

Jinping Sun, Wei Wang, Quanrui Ma, Xiaoli Pan, Hualiang Zhai, Junyan Wang, Yong Han, Yunhong Li, Yin Wang

Erratum issuedOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Necrostatin-1: a promising compound for neurological disorders.Frontiers in cellular neuroscience · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jinping SunSchool of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Wei WangDepartment of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Quanrui MaSchool of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Xiaoli PanDepartment of Pathology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Hualiang ZhaiDepartment of Pathology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Junyan WangSchool of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Yong HanSchool of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Yunhong LiSchool of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China. 976153438@qq.com.
Yin WangSchool of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China. yin-wang@hotmail.com.
Ningxia Medical University · CN

Funding

Key Research and Development Plan of Ningxia 2021BEG03097National Natural Science Foundation of China 32160192National Natural Science Foundation of China 82060223Natural Science Foundation of Ningxia 2022AAC03607
6 · The paper itself

Abstract

Periventricular leukomalacia (PVL), a predominant form of brain injury in preterm survivors, is characterized by hypomyelination and microgliosis and is also the major cause of long-term neurobehavioral abnormalities in premature infants. Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in mediating cell death and inflammatory signaling cascade. However, very little is known about the potential effect of RIPK1 in PVL and the underlying mechanism. Herein, we found that the expression level of RIPK1 was drastically increased in the brain of PVL neonatal mice models, and treatment of PVL neonatal mice with Necrostatin-1s (Nec-1s), an inhibitor of RIPK1, greatly ameliorated cerebral ischemic injury, exhibiting an increase of body weights, reduction of cerebral infarct size, neuronal loss, and occurrence of necrosis-like cells, and significantly improved the long-term abnormal neurobehaviors of PVL. In addition, Nec-1s significantly suppressed hypomyelination and promoted the differentiation of oligodendrocyte precursor cells (OPCs), as demonstrated by the increased expression levels of MBP and Olig2, the decreased expression level of GPR17, a significant increase in the number of CC-1-positive cells, and suppression of myelin ultrastructure impairment. Moreover, the mechanism of neuroprotective effects of Nec-1s against PVL is closely associated with its suppression of the RIPK1-mediated necrosis signaling molecules, RIPK1, PIPK3, and MLKL. More importantly, inhibition of RIPK1 could reduce microglial inflammatory injury by triggering the M1 to M2 microglial phenotype, appreciably decreasing the levels of M1 marker CD86 and increasing the levels of M2 markers Arg1 or CD206 in PVL mice. Taken together, inhibition of RIPK1 markedly ameliorates the brain injury and long-term neurobehavioral abnormalities of PVL mice through the reduction of neural cell necroptosis and reversing neuroinflammation.

Indexed as

Brain InjuriesLeukomalacia, PeriventricularAnimalsAnimals, NewbornHumansImidazolesIndolesInfantInfant, NewbornInflammationMiceNecroptosisNecrosisNerve Tissue ProteinsReceptor-Interacting Protein Serine-Threonine KinasesReceptors, G-Protein-CoupledGPR17 protein, humanGPR17 protein, mouseImidazolesIndolesnecrostatin-1Nerve Tissue ProteinsReceptor-Interacting Protein Serine-Threonine KinasesReceptors, G-Protein-CoupledRIPK1 protein, humanNecrosisOligodendrocyte precursor cellsPeriventricular leukomalaciaRIPK1

Identifiers

PMID37642893
OpenAlexW4386253724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.